CLINICAL SCIENCE

SHORT-TERM RED WINE CONSUMPTION PROMOTES DIFFERENTIAL EFFECTS ON PLASMA LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, SYMPATHETIC ACTIVITY, AND ENDOTHELIAL FUNCTION IN HYPERCHOLESTEROLEMIC, HYPERTENSIVE, AND HEALTHY SUBJECTS

Ana CM Andrade, Fernando HY Cesena, Fernanda M Consolim-Colombo, Silmara R Coimbra, Alexandre M Benjô, Eduardo M Krieger, Protasio Lemos da Luz

doi: 10.1590/S1807-59322009000500011

OBJECTIVES: To compare the metabolic, hemodynamic, autonomic, and endothelial responses to short-term red wine consumption in subjects with hypercholesterolemia or arterial hypertension, and healthy controls.

METHODS: Subjects with hypercholesterolemia (n=10) or arterial hypertension (n=9), or healthy controls (n=7) were given red wine (250 mL/night) for 15 days. Analyses were performed before and after red wine intake.

RESULTS: Red wine significantly increased the plasma levels of HDL-cholesterol in the controls, but not in the other groups. The effects on hemodynamic measurements were mild, non-significantly more prominent in healthy subjects, and exhibited high interindividual variability. Across all participants, mean blood pressure decreased 7 mmHg (p <0.01) and systemic vascular resistance decreased 7% (p = 0.05). Heart rate and cardiac output did not significantly change in any group. Red wine enhanced muscle sympathetic fibular nerve activity in hypercholesterolemic and hypertensive patients, but not in controls. At baseline, brachial artery flow-mediated dilation was impaired in patients with hypercholesterolemia and arterial hypertension; red wine restored the dilation in the hypercholesterolemic group but not in the hypertensive group.

CONCLUSIONS: Red wine elicits different metabolic, autonomic, and endothelial responses among individuals with hypercholesterolemia or arterial hypertension and healthy controls. Our findings highlight the need to consider patient characteristics when evaluating the response to red wine.

KEYWORDS: Alcohol; Red Wine; Endothelial Function; Flow-mediated Dilation; Sympathetic Activity

INTRODUCTION

Several studies have documented a protective role of moderate wine consumption (15.5 to 31 g alcohol/day) in both vascular and nonvascular diseases. Different mechanisms may be responsible for these beneficial effects, including increases in HDL-cholesterol plasma levels, decreased platelet aggregation, antioxidant effects, and restoration of endothelial function by flavonoids.

On the other hand, high alcohol intake (> 31 g alcohol/day) is associated with undesirable consequences, such as elevation of blood pressure and activation of the sympathetic system. Epidemiological studies consistently show a J-shaped relation between alcohol consumption and total mortality.

We have previously shown that red wine and purple grape juice restore endothelial function in hypercholesterolemic individuals without any additional risk factors. It is not well known whether this beneficial effect is reproducible in people with other conditions that may be associated with...
endothelial dysfunction such as arterial hypertension. In fact, the influence of different risk factors on the various properties of red wine has not been fully investigated. Studies comparing the different effects of red wine in populations with different characteristics are lacking.

We have put forward the hypothesis that the effects of red wine on different aspects related to cardiovascular disease may differ according to individual characteristics, specifically whether the subject is hypertensive or hypercholesterolemic.

Hence, the purpose of this study was to compare the effects of 15 days of red wine consumption on the lipid profile, hemodynamic profile, sympathetic activity, and endothelial function of patients with hypercholesterolemia or arterial hypertension and in healthy controls.

MATERIALS AND METHODS

Subjects and protocol

Ten subjects with hypercholesterolemia (HCHOL group), nine with arterial hypertension (AH group), and seven with neither hypercholesterolemia nor arterial hypertension (healthy controls) were enrolled. Arterial hypertension was defined as blood pressure (BP) >140/90mm Hg, according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypercholesterolemia was defined as a plasma LDL-cholesterol >160 mg/dL. None of the subjects had clinical evidence of any serious disease or condition that alters sympathetic activity such as diabetes mellitus; heart, liver, or renal failure; obesity; smoking; old age (>65 years); or peripheral neuropathies. They were asked not to ingest products containing caffeine or polyphenols, such as fruit, coffee, tea, and alcoholic beverages other than the wine used in the study, during the 72 hours preceding the protocol examinations. They were encouraged not to change their daily dietary habits otherwise. They were not taking statins, and they were told to stop taking any antihypertensive drugs three weeks before the beginning of the protocol. Any possible harmful effects of medication withdrawal were monitored with periodic blood pressure (BP) measurements and active questioning of the subjects.

Blood collection (after a 12-hour overnight fast), analyses of endothelial function (in the morning) and sympathetic activity, and blood analysis

Plasma levels of total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and glucose were determined by enzymatic methods (Roche Laboratories, Basel, Switzerland).

Microneurography protocol

Muscle sympathetic nerve activity (MSNA) was assessed by direct multiunit recordings of postganglionic sympathetic activity of the fibular nerve. The procedure involved selective insertion of unipolar tungsten microelectrodes into nerve fibers in the muscle, posterior to the fibular head, according to a previously described technique. Filtered and mean neurograms were recorded on millimetered paper. Muscle sympathetic bursts were identified by visual inspection by a single blinded investigator (F.C.C.) and were expressed as bursts per minute.

Hemodynamic variables

During the microneurography protocol, HR, BP, and electrocardiography (DII lead) were continuously monitored. BP was measured noninvasively, beat-to-beat, using a photoplethysmographic finger device (Portapres, Finapres Medical Systems, The Netherlands). This method is based on a volume-clamp technique, and the mean BP is obtained as the integral of pressure over each beat divided by the corresponding beat interval. Measurements were transferred to a computer for calculation.
of several hemodynamic variables (including cardiac output and systemic vascular resistance) using commercial software (BeatScope 1.1, Finapres Medical Systems, The Netherlands).

**Brachial artery reactivity protocol**

Brachial artery ultrasound studies were performed to assess endothelial function by measuring flow-mediated dilation (FMD) induced by reactive hyperemia as previously described\(^8\) and according to current guidelines.\(^{16}\) Studies were performed after the patient had rested for 10 minutes in a temperature-controlled room (20° to 25°C) using a 7.5-MHz linear array vascular ultrasound transducer and an APOGEE 800 plus ATL ultrasound system (ATL Ultrasound, Bothell, WA, USA).

The left brachial artery was imaged 2 to 15 cm above the elbow and scanned in longitudinal section with the focus zone set to the depth of the near wall. During image acquisition, anatomic landmarks such as fascial planes were noted to help record the same image of the artery throughout the study. Vessel diameter was measured using specific software developed at the Heart Institute (São Paulo, Brazil) that uses a semiautomatic approach to measure artery diameter based on an active contour technique supplemented by multisresolution analysis\(^8\). The blinded operator selected a region of interest (0.39 inch in longitudinal diameter) in 6 series of brachial artery images obtained from B-mode ultrasound. The distance between the near and far wall media-adventitia during diastole was obtained for all images, and the average was calculated.

Reactive hyperemia was induced by inflation of a pneumatic BP tourniquet, placed around the forearm, to a systolic BP of 250 mm Hg, followed by deflation after 5 minutes. FMD was calculated as the ratio of the brachial artery diameter after reactive hyperemia to the baseline diameter, expressed as percent variation.

Endothelium-independent vasodilation was assessed by administration of sublingual isosorbide dinitrate (5 mg) and calculated in an analogous fashion. The average of two measurements was taken.

**Statistical analysis**

Continuous variables were reported as mean ± standard deviation (SD), unless otherwise noted. Data were compared using the paired Student’s \(t\) test or analysis of variance (ANOVA) with repeated measurements, and post hoc analyses were performed to determine differences between two groups and/or two moments (for instance, after vs. before red wine intake).

Correlation analyses were also performed to assess interdependence between changes in different variables after red wine intake.

The level of significance was taken to be \(p < 0.05\) for all analyses.

**RESULTS**

**Clinical and laboratory data**

Table 1 summarizes the clinical and laboratory characteristics of the three groups before and after red wine consumption. Groups were comparable in terms of gender and age distributions. As expected, the HCHOL group exhibited higher plasma levels of total cholesterol and LDL-cholesterol compared with the AH and control groups and higher plasma concentrations of triglycerides compared with controls. Both the AH and HCHOL groups exhibited higher glucose levels than the controls, and the hypertensive

| Table 1 - Clinical and laboratory data of patients before and after red wine intake |
|------------------|------------------|------------------|------------------|
|                   | Hypercholesterolemia (n=10) | Arterial hypertension (n=9) | Control (n=7) |
|                   | Before red wine | After red wine | Before red wine | After red wine | Before red wine | After red wine |
| Sex (men/women)  | 7/3 | 7/2 | 5/2 |
| Age (years)      | 43.2 ± 6.9 | 45.1 ± 7.4 | 37.3 ± 7.2 |
| BMI (kg/m\(^2\)) | 25.6 ± 2.9 | 25.8 ± 3.0 | 27.9 ± 1.9\(^d\) | 28.1 ± 1.9 | 24.5 ± 2.9 | 24.4 ± 2.7 |
| Total cholesterol (mg/dL) | 259 ± 19\(^a\) | 242 ± 37 | 199 ± 45 | 192 ± 51 | 172 ± 23 | 194 ± 38 |
| LDL-cholesterol (mg/dL) | 181 ± 17\(^a\) | 164 ± 31 | 131 ± 38 | 117 ± 39 | 106 ± 15 | 119 ± 27 |
| HDL-cholesterol (mg/dL) | 53 ± 9 | 49 ± 9 | 47 ± 10 | 48 ± 10 | 52 ± 12 | 59 ± 16\(^e\) |
| Triglycerides (mg/dL) | 126 ± 46\(^a\) | 139 ± 66 | 100 ± 36 | 131 ± 51\(^f\) | 70 ± 24 | 81 ± 30 |
| Glucose (mg/dL) | 97 ± 9 | 99 ± 10 | 97 ± 8 | 101 ± 9 | 88 ± 7\(^c\) | 91 ± 5 |

BMI: body mass index; Data are reported as mean ± SD; \(^a\) \(p < 0.01\) vs. AH or control before red wine; \(^b\) \(p = 0.04\) vs. control before red wine; \(^c\) \(p \leq 0.04\) vs. AH or HCHOL before red wine; \(^d\) \(p = 0.03\) vs. control before red wine; \(^e\) \(p = 0.02\) vs. before red wine.
individuals recorded a higher average body mass index than the controls.

When all patients were grouped together, red wine intake significantly increased plasma concentrations of triglycerides (21%, p < 0.01) and glucose (3%, p = 0.03). A significant elevation in HDL-cholesterol plasma levels after red wine intake was observed only in the healthy controls (14%, p = 0.02).

**Hemodynamic measurements and sympathetic activity**

**Resting condition**

Before red wine intake, systolic BP was significantly higher in the AH group compared with controls. Also, diastolic BP was nonsignificantly higher in the AH group than in the other groups, and, as expected, mean BP was significantly higher in the AH group than in the other groups (Table 2). This finding was not associated with significant differences in resting MSNA among the three groups (Table 3).

Although red wine markedly increased resting MSNA in the HCHOL and AH groups, the variation in healthy controls was minimal (Table 3). Indeed, after red wine intake, the peripheral sympathetic system was significantly more activated in the hypertensive and hypercholesterolemic individuals than in the healthy controls (Table 3).

In contrast with this sharp increase in sympathetic activity in the HCHOL and AH groups, the hemodynamic consequences of red wine were mild, non-significantly more prominent in healthy subjects (Table 2), and characterized by a high interindividual variability, especially in the HCHOL and AH groups.

Grouping all the patients together, red wine reduced systolic BP from 143 ± 13 mmHg to 138 ± 13 mmHg (p = 0.01), diastolic BP from 84 ± 9 mmHg to 78 ± 8 mmHg (p < 0.01), and mean BP from 108 ± 11 mmHg to 101 ± 10 mmHg (p < 0.01). This effect was likely driven by a fall in systemic vascular resistance, which decreased 7% across all patients (p = 0.05 vs. before red wine), 1% in the HCHOL group, 8% in the AH group, and 17% in the controls (p = ns for comparison among groups). No significant change was found in the variation of the cardiac output or HR after red wine consumption in any group (Table 2).

No correlation was detected between the variation in resting MSNA (after vs. before red wine) and either the change in mean BP or systemic vascular resistance.

**Effects of cold stimulus**

As expected, cold stimulus increased MSNA (26% before, 36% after red wine intake, p ≤ 0.01 vs. resting condition, across all patients).

Before the red wine intake, cold stimulus caused systolic

| Table 2 - Hemodynamic data at rest, before and after red wine intake |
|---------------------------------------------------------------|
| **Hypercholesterolemia** (n=10) | **Arterial hypertension** (n=9) | **Control** (n=7) |
| Heart rate (bpm) | Before red wine | After red wine | Before red wine | After red wine | Before red wine | After red wine |
| 68 ± 9 | 68 ± 11 | 76 ± 14 | 75 ± 10 | 69 ± 13 | 71 ± 6 |
| Systolic BP (mmHg) | 141 ± 15 | 135 ± 12 | 153 ± 8 | 149 ± 8 | 134 ± 6 | 129 ± 8 |
| Diastolic BP (mmHg) | 80 ± 11 | 75 ± 7 | 89 ± 5 | 85 ± 6 | 83 ± 7 | 73 ± 7 |
| Mean BP (mmHg) | 104 ± 13 | 97 ± 8 | 116 ± 6 | 111 ± 6 | 103 ± 9 | 94 ± 6 |
| Cardiac output (L/min) | 6.32 ± 1.25 | 6.14 ± 1.08 | 6.19 ± 0.98 | 6.55 ± 1.26 | 5.70 ± 1.37 | 6.46 ± 1.27 |
| Systemic vascular resistance (dyne.s.cm⁻¹) | 1037 ± 291 | 981 ± 170 | 1208 ± 283 | 1072 ± 283 | 1158 ± 386 | 919 ± 245 |

BP: blood pressure; Data are reported as mean ± SD; ¹ p = 0.01 vs. control before red wine; ² p < 0.01 vs. HCHOL or control before red wine; ³ p ≤ 0.03 vs. control after red wine; ⁴ p < 0.01 vs. HCHOL or control after red wine; ⁵ p ≤ 0.03 vs. before red wine

| Table 3 - Muscle sympathetic nerve activity (bursts/min) before and after red wine intake |
|---------------------------------------------------------------|
| **Hypercholesterolemia** (n=10) | **Arterial hypertension** (n=9) | **Control** (n=7) |
| Rest | Before red wine | After red wine | Before red wine | After red wine | Before red wine | After red wine |
| 27.0 ± 6.8 | 49.9 ± 5.5 | 30.0 ± 8.0 | 42.7 ± 9.6 | 26.6 ± 7.1 | 26.9 ± 8.8 |
| Cold stimulus | 31.2 ± 6.5 | 62.9 ± 9.2 | 36.9 ± 11.1 | 58.1 ± 11.9 | 33.9 ± 5.0 | 37.4 ± 6.6 |
| Isometric exercise | 34.4 ± 9.1 | 55.8 ± 10.9 | 36.1 ± 15.9 | 51.2 ± 13.6 | 31.1 ± 5.8 | 37.4 ± 7.4 |

Data are reported as mean ± SD; ¹ p ≤ 0.02 vs. before red wine; ² p ≤ 0.02 vs. HCHOL or AH at rest, after red wine; ³ p < 0.01 vs. HCHOL or AH at cold test, after red wine; ⁴ p < 0.01 vs. HCHOL at isometric exercise, after red wine
and diastolic BP to increase 21 ± 10% and 19 ± 10%, respectively (p ≤0.01 vs. resting condition, considering all patients). After consuming red wine, the corresponding values were 23 ± 10% and 21 ± 9% (p ≤0.01 vs. resting condition, across all patients). There was no significant difference among the three groups in terms of blood pressure variation with the cold stimulus either before or after red wine intake.

Although it did not attain statistical significance, the increase in systemic vascular resistance with the cold stimulus was less pronounced after vs. before red wine, especially in healthy subjects. In the HCHOL group, the increase was 20% before and 12% after red wine; in the AH group, the numbers were 46% and 40%, respectively; in controls, 22% and 7%, respectively.

Effects of isometric exercise

As expected, isometric exercise increased MSNA (31% before, 26% after red wine intake, p ≤0.02 vs. resting condition, across all patients). The effects of isometric exercise on hemodynamic measurements were more modest than those reported for the cold test. Before red wine intake, grouping all the patients together, both systolic and diastolic BP increased 7% (p <0.01), and systolic vascular resistance increased 6% (p = 0.07). The magnitude of these isometric exercise-induced variations was unchanged by red wine. In addition, no significant difference was observed among the groups.

Brachial artery reactivity

Before red wine intake, FMD was nonsignificantly lower in the HCHOL and AH groups compared to the controls (Figure 1). Red wine restored FMD in the HCHOL group, but not in the AH group. Endothelium-independent vasodilation was nonsignificantly impaired in the AH group compared with the HCHOL group and controls, both before or after red wine consumption.

We also sought to evaluate the subset of 14 individuals who performed the brachial artery reactivity test after a washout period. In five HCHOL subjects, the FMD was 6.9 ± 12.3% at the beginning of the study, increased to 14.7 ± 2.8% after red wine, and fell to -0.4 ± 7.4% after red wine washout, indicating, on average, an absence of FMD following red wine withdrawal. In seven hypertensive patients, FMD was 4.7 ± 1.5%, 5.2 ± 5.7%, and 3.6 ± 2.2% before red wine, after red wine, and after washout, respectively. In two healthy subjects, the respective dilations were 13.1 ± 1.7%, 15.8 ± 1.9%, and 14.8 ± 6.1%.

There was no correlation between changes in either MSNA or systemic vascular resistance (after vs. before red wine intake) and variation in FMD.

DISCUSSION

Numerous cross-sectional, observational, and controlled studies reveal a range of red wine effects on different aspects related to cardiovascular disease.3,17 Other studies show the relations of essential hypertension and coronary disease with genetic background,18 capillary density,19 and blood levels of cholesterol.20,21 Most of these studies have addressed one or a few outcomes, and not several at the same time, as in the current investigation. Moreover, most of the previous controlled trials have enrolled only healthy people17 and have not compared different populations simultaneously.

Our objectives were to compare the metabolic, hemodynamic, autonomic, and endothelial responses to red wine in subjects with hypercholesterolemia or arterial hypertension, or in healthy controls with neither of these risk factors. Several major findings are contributed by this study: (1) red wine increased plasma HDL-cholesterol levels only in the control group; (2) red wine slightly decreased mean BP in all groups, which was associated with a borderline-significant fall in systemic vascular resistance; (3) red wine caused a significant increase in sympathetic activity in the HCHOL and AH groups but not in controls; and (4) red wine restored FMD in the HCHOL group but not in the AH group.
Short-term red wine consumption promotes differential effects
Andrade ACM et al.

Metabolic changes

Several studies have documented the effects of alcoholic beverages on lipid metabolism. In particular, the HDL-cholesterol-raising property of red wine seems to be primarily dependent on the alcoholic content, given that one head-to-head comparison shows that red wine, but not red grape extract, increases blood HDL-cholesterol concentrations.

In a meta-analysis of studies evaluating different ethanol-containing drinks in mostly healthy individuals, Rimm et al. reported that 30 g of ethanol per day increases the plasma concentration of HDL-cholesterol by 4 mg/dL and of triglycerides by 6 mg/dL. Thus, the increase in triglyceride levels that we observed is consistent, although more than 3-fold higher, than that reported by Rimm et al.

The present study revealed that the increase in plasma HDL-cholesterol concentration was restricted to healthy subjects. In a previous investigation, we also observed no increase in HDL-cholesterol levels after 14 days of red wine ingestion in individuals with a high baseline plasma concentration of total cholesterol. One possible explanation for this finding is related to individuals being overweight or obese. In our cohort, healthy controls were thinner than the hypercholesterolemic or hypertensive patients. Interestingly, Hagiage et al. demonstrated that wine (30 g ethanol for 14 days) increases apolipoprotein A1 and decreases cholesteryl ester transfer protein activity in normoponderal but not in obese subjects, suggesting that obesity-associated abnormalities impair the effects of wine on HDL metabolism.

The very mild elevation in plasma glucose levels after red wine intake and the short-term nature of this study do not allow speculation as to the possible undesirable consequences of long-term alcohol intake on glucose metabolism. However, available data from the literature point in the opposite direction: population studies show that low-to-moderate regular alcohol intake decreases insulinemia and improves insulin sensitivity. In addition, alcohol consumption was recently inversely associated with the risk of type 2 diabetes in women in a case-control study.

Hemodynamic measurements

Chronic heavy alcohol ingestion is consistently associated with hypertension. Although more controversial, moderate alcohol/red wine consumption is also believed to raise blood pressure, although an acute, transitory fall is reported to happen in the first hours after alcohol ingestion.

Our study does not support the belief that moderate, short-term red wine consumption increases BP. Despite a high interindividual variability in our hemodynamic data that prevents definitive conclusions, red wine intake decreased the average BP in association with a quasi-significant fall in systemic vascular resistance. Interestingly, this decrease in BP was not observed in our previous investigation, using a very similar protocol.

Differences in the type of wine used and the manner of measuring BP (standard pneumotachographic method in the forearm vs. plethysmographic finger device) may explain these contrasting results.

Importantly, the decrease in systemic vascular resistance cannot be attributed to changes in either sympathetic activity or endothelial function, suggesting a direct vasodilatory action of red wine. The less-pronounced elevation in systemic vascular resistance with the cold test after red wine consumption is also consistent with a vasodilatory property of red wine.

It is interesting to note that red wine increased sympathetic outflow only in the HCHOL and AH groups, whereas hemodynamic changes (decreases in BP and systemic vascular resistance) were nonsignificantly less expressive in these groups, as compared to controls. In addition, the attenuating effect of red wine on the increase in systemic vascular resistance with cold stimulus was more evident in healthy individuals. Although we found no correlation among variations (after vs. before red wine) in terms of MSNA, systemic vascular resistance, and FMD, these observations allow us to suggest that red wine decreases systemic vascular resistance and BP through a direct vasodilatory effect, but that activation of the sympathetic system (possibly by alcohol) blunts these hemodynamic effects.

Sympathetic activity

Previous studies have shown that acute alcohol or red wine ingestion increases sympathetic activity in healthy volunteers, in disagreement with the lack of increase in MSNA in our control group. It is possible that this discrepancy reflects the longer duration of and more moderate nature of alcohol intake in our study.

The reason why red wine increased MSNA in the HCHOL and AH groups but not in controls is not clear. Although speculative, it may be true that individuals with lipid disorders and those with hypertension share some abnormality that is responsible for the different effects of ethanol or red wine on autonomic activity, compared with normal individuals. A very reasonable candidate is the baroreflex dysfunction, which is known to be a feature of arterial hypertension and other conditions closely related to lipid abnormalities such as coronary artery disease, diabetes mellitus, obesity, and metabolic syndrome. Accordingly,
baroreceptor impairment may be implicated in some ethanol effects.\cite{30} Therefore, the baroreflex dysfunction might be the link between red wine intake and increased MSNA in the HCHOL and AH groups, but not in healthy persons.

**Endothelial function**

The increase in FMD after red wine consumption in hypercholesterolemic subjects confirms our previous findings\cite{8} and supports the results of other studies that show acute benefits of wine or de-alcoholized red wine on the endothelium in patients with coronary artery disease.\cite{31,32} In the present study, in particular, the obvious fall in FMD after the washout period (this actually suggests a rebound effect) clearly supports a beneficial role of red wine components as they impact the endothelium in this population. This effect is most likely related to higher nitric oxide bioavailability.\cite{33,34}

The lack of improvement in endothelial function in our hypertensive patients should be confirmed with further studies. Assuming endothelial dysfunction is an accepted marker of early atherosclerosis and has prognostic relevance,\cite{35} this finding has important clinical implications. We note, however, that endothelium-independent vasodilation was nonsignificantly lower in the AH group, which might have influenced the results of the reactive hyperemia.

Although our study failed to determine why the endothelial response to red wine was inconsistent between individuals with hypercholesterolemia or hypertension, we suggest that different mechanisms may account for endothelial dysfunction under such conditions. In support of this possibility, two studies from the same group have demonstrated that, in patients with essential hypertension, endothelium-dependent vasodilation in response to bradykinin is impaired. This contrasts with a preserved response to bradykinin in hypercholesterolemic subjects.\cite{36,37}

**Limitations**

Our sample size may not have been sufficiently large to detect certain differences in the effects of red wine among the groups. We emphasize that this study evaluated the effects of short-term red wine intake, and our conclusions should not be extrapolated to longer-term ingestion scenarios. Endothelial function was analyzed using only one method, as was sympathetic activity. Mechanistic investigations, such as those involved in baroreflex dysfunction, were not performed. The lack of measurement of concentrations of resveratrol, catechin, or quercetin in plasma or urine does not allow us to reach firm conclusions regarding the effects of flavonoids in this study.

**CONCLUSIONS**

This study highlights the existence of significant variability in the effects of red wine on different patient groups. Elevation in HDL-cholesterol levels was noted only in healthy subjects, but not in those with arterial hypertension or high total cholesterol levels. Hemodynamic consequences of red wine intake were somewhat variable among subjects across all groups; on average, red wine decreased mean BP, probably due to a direct vasodilatory action. Red wine activated the sympathetic system in individuals with hypercholesterolemia or arterial hypertension, but not in healthy controls. In terms of improving endothelial function, individuals with hypertension do not benefit from red wine as hypercholesterolemic subjects do.

Further investigations involving larger samples are required to confirm and understand the mechanisms involved in these findings and, consequently, to provide therapeutic implications. So far, the results reinforce the need for us to consider patient characteristics when evaluating the medical properties of red wine.

**ACKNOWLEDGEMENTS**

This study was supported by FAPESP - The State of São Paulo Research Foundation (number 03/09084-0) – São Paulo-SP, Brazil.

**REFERENCES**

1. da Luz PL, Coimbra SR. Wine, alcohol and atherosclerosis: clinical evidences and mechanisms. Braz J Med Biol Res. 2004;37:1275-95.
2. Klatsky AL, Friedman GD, Armstrong MA, Kipp H. Wine, liquor, beer, and mortality. Am J Epidemiol. 2003;158:585-95.
3. Opie LH, Lecour S. The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J. 2007;28:1683-93.
4. Nishiwaki M, Ishikawa T, Ito T, Shige H, Tomiyasu K, Nakajima K, et al. Effects of alcohol on lipoprotein lipase, hepatic lipase, cholesteryl ester transfer protein, and lecithin:cholesterol acyltransferase in high-density lipoprotein cholesterol elevation. Atherosclerosis. 1994;111:99-109.
5. Ruf JC. Alcohol, wine and platelet function. Biol Res. 2004;37:209-15.
6. Durak I, Avci A, Kaçmaz M, Büyükköçak S, Cimen MY, Elgün S, et al. Comparison of antioxidant potentials of red wine, white wine, grape juice and alcohol. Curr Med Res Opin. 1999;15:316-20.
7. Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation. 1999;100:1050-55.
Short-term red wine consumption promotes differential effects
Andrade ACM et al.

8. Coimbra SR, Lage SH, Brandizzi L, Yoshida V, da Luz PL. The action of red wine and purple grape juice on vascular reactivity is independent of plasma lipids in hypercholesterolemic patients. Braz J Med Biol Res. 2005;38:1339-47.

9. Zilkens RR, Burke V, Hodgson JM, Barden A, Beilin LJ, Puddey IB. Red wine and beer elevate blood pressure in normotensive men. Hypertension. 2005;45:874-9.

10. McFadden CB, Brensinger CM, Berlin JA, Townsend RR. Systematic review of the effect of daily alcohol intake on blood pressure. Am J Hypertens. 2005;18:276-86.

11. Grassi GM, Somers VK, Renk WS, Abboud FM, Mark AL. Effects of alcohol intake on blood pressure and sympathetic nerve activity in normotensive humans: a preliminary report. J Hypertens. Suppl 1989;7:820-1.

12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-52.

13. Delius W, Hagbarth KE, Hungell A, Wallin BG. General characteristics of sympathetic activity in human muscle acts. Acta Physiol Scand. 1972;84:65-81.

14. Harms MP, Wesseling KH, Pott F, Jenstrup M, Van Goudoever J, Secher NH et al. Continuous stroke volume monitoring by modelling flow from non-invasive measurement of arterial pressure in humans under orthostatic stress. Clin Sci (Lond). 1999;97:291-301.

15. Imholz BP, Wiebing W, van Montfrans GA, Wesseling KH. Fifteen years experience with finger arterial pressure monitoring: assessment of the technology. Cardiovasc Res. 1998;38:605-16.

16. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-65.

17. Rimm EB, Williams P, Fosher K, Criqui M, Stamper MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999;319:1523-8.

18. Lopes HF, Consolim-Colombo FM, Barreto-Filho JA, Riccio GM, Negrao CE, Krieger EM. Increased sympathetic activity in normotensive offspring of malignant hypertensive parents compared to offspring of normotensive parents. Braz J Med Biol Res. 2008;41:849-53.

19. Pennu GL, Garbero R de F, Neves MF, Oigmam W, Bottino DA, Bouskela E. Treatment of essential hypertension does not normalize capillary rarefaction. Clinics. 2008;63:613-8.

20. Crisostomo LM, Souza CA, Mendes CM, Coimbra SR, Favaro D, Luz PL. Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly. metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly. Clinics. 2008;63:589-94.

21. Luz PL, Favaro D, Faria-Neto JR, Lemos P, Chagas AC. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics. 2008;63:427-32.

22. Hansen AS, Marckmann P, Dragsted LO, Finné Nielsen IL, Nielsen SE, Gronbaek M. Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk factors for cardiovascular disease. Eur J Clin Nutr. 2005;59:449-55.

23. Hagiage M, Marti C, Rigaud D, Senault C, Fumeron F, Apfelbaum M, et al. Effect of a moderate alcohol intake on the lipoproteins of normotriglyceridemic obese subjects compared with normoponderal controls. Metabolism. 1992;41:856-61.

24. Kiechl S, Willeit J, Poewe W, Egger G, Oberhollenzer F, Muggeo M, et al. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study). BMJ. 1996;313:1040-4.

25. Freiberg MS, Cabral HJ, Heeren TC, Vasan RS, Curtis Ellison R; Third National Health and Nutrition Examination Survey. Alcohol consumption and the prevalence of the Metabolic Syndrome in the US: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27:2954-9.

26. Beulens JW, Rimm EB, Hu FB, Hendriks HF, Mukamal KJ. Alcohol consumption, mediating biomarkers and risk of type 2 diabetes among middle-aged women. Diabetes Care. 2008;31:2050-5.

27. van de Borne P, Mark AL, Montano N, Mion D, Somers VK. Effects of alcohol on sympathetic activity, hemodynamics, and chemoreflex sensitivity. Hypertension. 1997;29:1278-83.

28. Spaak J, Merlocco AC, Soleas GJ, Tomlinson G, Morris BL, Picton P, et al. Dose-related effects of red wine and alcohol on hemodynamics, sympathetic nerve activity, and arterial diameter. Am J Physiol Heart Circ Physiol. 2008;294:H605-12.

29. Skrapari I, Tentolouris N, Katsilambros N. Baroreflex function: determinants in healthy subjects and disturbances in diabetes, obesity and metabolic syndrome. Curr Diabetes Ver. 2006;2:329-38.

30. Abdel-Rahman AA, Wooles WR. Ethanol-induced hypertension involves impairment of baroreceptors. Hypertension. 1987;10:67-73.

31. Whelan AP, Sutherland WH, McCormick MP, Yeoman DJ, de Jong SA, Williams MJ. Effects of white and red wine on endothelial function in subjects with coronary artery disease. Intern Med J. 2004;34:224-8.

32. Karatzi K, Papamichael C, Aznaouridis K, Karatzis E, Lekakis J, Matsouka C et al. Constituents of red wine other than alcohol improve endothelial function in patients with coronary artery disease. Coron Artery Dis. 2004;15:485-90.

33. Andriambeloson E, Stoclet JC, Andriantsitohaina R. Mechanism of endothelial nitric oxide-dependent vasorelaxation induced by wine polyphenols in rat thoracic aorta. J Cardiovasc Pharmacol. 1999;33:248-54.

34. Puddey IB, Zilkens RR, Croft KD, Beilin LJ. Alcohol and endothelial function: a brief review. Clin Exp Pharmacol Physiol. 2001;28:1020-4.

35. Münzel T, Sinning C, Post F, Warnholz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med. 2008;40:180-96.

36. Gilligan DM, Guetta V, Panza JA, García CE, Quyyumi AA, Cannon RO 3rd. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation. 1994;90:35-41.

37. Panza JA, García CE, Kilcoyne CM, Quyyumi AA, Cannon RO 3rd. Impaired endothelium-dependent vasodilatation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation. 1995;91:1732-8.